Patent ID: 11865359
Assignee: IMMUNOLIGHT, LLC
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 49:
50. A system for imaging or treating a disease in a human or animal body, comprising:
a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide imaging contrast;
one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier;
an initiation energy source comprising a source of radiation which direct penetrating radiation to the diseased site to thereby initiate emission of said ultraviolet or visible light into the body; and
a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of the penetrating radiation to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug,
wherein the processor further controls the x-ray, gamma rays, or electrons during a booster treatment repeated on a periodic basis after an initial treatment of the diseased site, wherein, in the booster treatment, at least one of phosphor concentration, photoactivatable drug concentration, and the dose of x-rays, gamma rays, or electrons is increased by a factor of at least two times, five times, or ten times respective initial values, wherein the booster treatment comprises one of (i) an additional administration of the photoactivatable drug to the diseased site followed by radiating the diseased site with the x-rays, gamma rays, or electrons; (ii) an additional administration of the photoactivatable drug and the pharmaceutical carrier including the one or more phosphors to the diseased site followed by radiating the diseased site with the x-rays, gamma rays, or electrons; or (iii) irradiating the diseased site with x-rays, gamma rays, or electrons at a palliative or therapeutic level; wherein the booster treatment activates an immune response that was initially or originally generated within the human or animal body prior to the booster treatment during initial treatments.